Streetbeat News

Earnings

MAPS

WM Technology, Inc. (NASDAQ:MAPS), also known as Weedmaps, reported its Q1 2024 financial results, showing a slight drop in revenue but improvements in net income and adjusted EBITDA. The company also reported a higher cash balance and an increase in average monthly revenue per paying client.

Portfolio Pulse from Jelena Martinovic

May 28, 2024 | 3:08 pm

AMD

INTC

NVDA

ORCL

SMCI

TSM

Nvidia shares surged after reports that Elon Musk's xAI plans to build a supercomputer using Nvidia chips. The supercomputer, expected to be operational by fall 2025, will be at least four times the size of the largest existing GPU clusters. Other chip stocks, including AMD, Micron, Intel, TSM, and Super Micro Computer, also saw movement. Nvidia's recent earnings beat estimates, and the company announced a 10-for-1 stock split and a 150% dividend increase.

Portfolio Pulse from Adam Eckert

May 28, 2024 | 3:07 pm

TXN

Elliott Management has acquired a $2.5 billion stake in Texas Instruments (NASDAQ: TXN) and is advocating for a more flexible capital expenditure approach to enhance free cash flow. Elliott's letter to the Board of Directors suggests that Texas Instruments' current Capex plan has significantly reduced free cash flow and shareholder returns. The hedge fund believes that adopting a dynamic capacity-management strategy could increase free cash flow to over $9 per share by 2026, exceeding current analyst consensus by around 40%.

Portfolio Pulse from Nabaparna Bhattacharya

May 28, 2024 | 3:07 pm

FIS

FISV

PYPL

The article provides a comprehensive analysis of Visa (NYSE:V) and its key competitors in the Financial Services industry. It highlights Visa's financial metrics, market position, and growth prospects, comparing them with those of its peers. Key takeaways include Visa's low PE ratio, high PB and PS ratios, strong ROE, EBITDA, and gross profit, but lower revenue growth compared to the industry average.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 3:00 pm

UNH

The article provides a comprehensive comparison of UnitedHealth Group (NYSE:UNH) against its key competitors in the Health Care Providers & Services industry. It highlights various financial metrics, market position, and growth prospects, indicating that UNH has a lower PE ratio, higher PB ratio, lower PS ratio, lower ROE, higher EBITDA, and gross profit but slower revenue growth compared to its peers.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 3:00 pm

AVGO

The article provides a comprehensive comparison of Broadcom (NASDAQ:AVGO) against its competitors in the Semiconductors & Semiconductor Equipment industry. It highlights Broadcom's financial metrics, market position, and growth prospects, noting its lower P/E ratio, higher P/B and P/S ratios, lower ROE, EBITDA, and gross profit, but strong revenue growth.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 3:00 pm

AMZN

INNPF

Innocan Pharma Corp. (OTCQB:INNPF) reported a 334% year-over-year revenue increase to $6.8 million for Q1 2024, despite a net loss of $1.5 million. The revenue growth was driven by strong sales from its subsidiary BI Sky Global Ltd. Increased expenses, particularly from Amazon platform commissions, contributed to the net loss.

Portfolio Pulse from Patricio Liddle

May 28, 2024 | 2:57 pm

Ralph Lauren shares are trading higher following the company's better-than-expected Q4 earnings report last week.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 2:42 pm

FCX

Recent options trading activity for Freeport-McMoRan (NYSE:FCX) shows a balanced sentiment among investors, with significant trades indicating a price range of $50.0 to $60.0. The stock is currently trading at $52.59, up by 2.06%, and may be approaching overbought territory. Analysts have a neutral outlook with a target price of $54.0.

Portfolio Pulse from Benzinga Insights

May 28, 2024 | 2:31 pm

AGIO

ARCT

CALT

GME

INSM

NVDA

Several US-listed stocks saw significant gains on Tuesday. Nvidia rose 4.4% due to reports of Elon Musk's xAI plans and strong financial results. Insmed climbed 110% after positive Phase 3 study results. Calliditas Therapeutics rose 74.6% following a board recommendation to accept a tender offer. Other notable gainers include Agios Pharmaceuticals, Arcturus Therapeutics, and GameStop.

Portfolio Pulse from Avi Kapoor

May 28, 2024 | 2:31 pm